Clinical and experimental toxicology: Exploring the new perspectives for drug safety assessment.

Erica Ashfaq*

Department of Medicine, University of Tasmania, Tasmania, Australia

Abstract

Clinical and experimental toxicology play pivotal roles in assessing the safety of drugs, identifying potential adverse effects, and guiding regulatory decisions. Over the years, advancements in toxicological research have provided valuable insights into the mechanisms underlying drug toxicity and have led to the development of more accurate and predictive models for safety assessment. This paper aims to explore new perspectives in clinical and experimental toxicology, focusing on the evolving methodologies and approaches that enhance drug safety assessment.

Keywords: Drug safety assessment, Adverse drug reactions, Animal models, Patient populations

Introduction

The traditional approach to drug safety assessment relies heavily on animal models and post-marketing surveillance to identify and manage adverse drug reactions. However, increasing concerns about the relevance of animal data to human toxicity and the need for more efficient and reliable methods have prompted a paradigm shift in toxicology research. The emergence of alternative testing strategies, such as in vitro cell-based models, organ-on-a-chip systems, and computational models, offers new opportunities for more accurate and human-relevant safety assessments [1].

In vitro cell-based models, including three-dimensional (3D) cell cultures and tissue-engineered systems, provide a closer approximation of human physiology and allow for the evaluation of drug effects on specific organ systems. These models can mimic the complex interactions between drugs and cells, providing valuable insights into their toxicity profiles and helping to identify potential adverse effects. Furthermore, advancements in tissue engineering techniques, such as the incorporation of microfluidic systems, enable the creation of organ-on-a-chip models that replicate the function and architecture of specific organs, allowing for more accurate toxicity assessments [2].

Computational models, including quantitative structure-activity relationship (QSAR) models, pharmacokinetic/pharmacodynamic (PK/PD) modeling, and systems biology approaches, are also gaining prominence in drug safety assessment. These models leverage the power of data analysis and computational algorithms to predict toxicity outcomes, evaluate drug interactions, and identify potential safety concerns. Additionally, the integration of multi-omics data (genomics, proteomics, metabolomics) with computational models offers a comprehensive understanding of the mechanisms underlying drug toxicity and aids in the identification of biomarkers for adverse drug reactions [3].

Furthermore, the advancement of personalized medicine and the development of biomarkers for individual susceptibility to drug toxicity are shaping the field of clinical and experimental toxicology. Genetic and genomic approaches enable the identification of genetic variations that influence drug metabolism and response, providing valuable insights into individual susceptibility to adverse drug reactions. Pharmacogenomics, the study of how an individual's genetic makeup influences their response to drugs, allows for personalized dosing regimens and improves drug safety [4].

In addition to methodological advancements, the integration of big data and real-world evidence has the potential to revolutionize drug safety assessment. Large-scale databases, electronic health records, and post-marketing surveillance systems can provide valuable information on drug safety profiles in diverse patient populations, leading to more comprehensive safety assessments and early detection of potential risks [5].

Conclusion

Clinical and experimental toxicology are undergoing significant transformations in drug safety assessment. The incorporation of in vitro models, computational approaches, personalized medicine, and real-world evidence is revolutionizing the field. These advancements offer new perspectives for more accurate and human-relevant safety assessments, ultimately leading to improved patient outcomes and more effective drug development and regulatory decision-making.

***Correspondence to** :Erica Ashfaq, Department of Medicine, University of Tasmania, Tasmania, Australia**.** E-mail: ashfaq09@utas.edu.au

***Received:** 05-June-2023, Manuscript No. AACETY-23-101374; **Editor assigned:** 06-June-2023, PreQC No. AACETY-23-101374 (PQ); **Reviewed:** 19-June-2023, QC No.AACETY-23-101374; **Revised:** 21-June-2023, Manuscript No. AACETY-23-101374 (R); **Published:** 28-June-2023, DOI: 10.35841/aacety-7.3.150*

***Citation:** Ashfaq E. Clinical and experimental toxicology: Exploring the new perspectives for drug safety assessment. J Clin Exp Tox. 2023 ;7(3):150*

References

1. Ismail Z, Creese B, Aarsland D, et al., . Psychosis in Alzheimer disease—Mechanisms, genetics and therapeutic opportunities. Nat Rev Neurol. 2022 ;18(3):131-44.
2. García-Gutiérrez V, Breccia M, Jabbour E, et al., . A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase. J Hematol Oncol. 2022 ;15(1):90.
3. Akbar M, Shabbir A, Rehman K, et al., . Neuroprotective potential of berberine in modulating Alzheimer's disease via multiple signaling pathways. J Food Biochem. 2021 ;45(10):e13936.
4. Carss KJ, Deaton AM, Diogo D, et al., . Using human genetics to improve safety assessment of therapeutics. Nat Rev Drug Discov. 2023 ; 22(2):145-62.
5. Eslami P, Sayarifard F, Safdari R, et al., . Global perspective on pediatric growth hormone registries: a systematic review J Pediatr Endocrinol Metab. 2022 ;35(6):709-26.

Citation: *Ashfaq E. Clinical and experimental toxicology: Exploring the new perspectives for drug safety assessment. J Clin Exp Tox. 2023 ;7(3):150*